Daly James M 4

What Happened
James M. Daly, a director of Cytokinetics, was awarded a total of 7,152 shares on May 27, 2026. The filing shows two grant entries: 2,851 shares reported at $0.00 (award/acquisition code A) and an additional 4,301 shares reported as a derivative award (also $0.00). These were reported as grants/awards, not open-market purchases or sales, so no cash was paid per the filing.

Key Details

• Transaction date: 2026-05-27 (filed 2026-05-27)
• Grants reported: 2,851 shares @ $0.00 (Award); 4,301 shares @ $0.00 (Award, reported as Derivative)
• Total shares granted: 7,152
• Reported acquisition price: $0.00 (no cash outlay recorded on Form 4)
• Shares owned after the transaction: Not specified in the filing
• Filing timeliness: Reported on the same date as the transaction (no late filing flag indicated)
• Transaction code: A = Award/Grant; derivative designation notes the second grant is a derivative-type award

Context
A derivative award typically means the grant may convert into common stock subject to vesting, performance or other conditions; the Form 4 does not indicate immediate sale or cashless exercise. Because these are awards (not purchases), they reflect compensation or incentive arrangements rather than a direct market sentiment signal.